In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
BackgroundTo characterize the clinical and pathological features and survival of patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer in China.MethodsThe China National Cancer Center database was used to identify 1,433 metastatic breast cancer patients with HER2-negative d...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.774577/full |
| _version_ | 1819284288649035776 |
|---|---|
| author | Yiqun Li Nilupai Abudureheiyimu Hongnan Mo Xiuwen Guan Shaoyan Lin Zijing Wang Yimeng Chen Shanshan Chen Qiao Li Ruigang Cai Jiayu Wang Yang Luo Ying Fan Peng Yuan Pin Zhang Qing Li Fei Ma Binghe Xu |
| author_facet | Yiqun Li Nilupai Abudureheiyimu Hongnan Mo Xiuwen Guan Shaoyan Lin Zijing Wang Yimeng Chen Shanshan Chen Qiao Li Ruigang Cai Jiayu Wang Yang Luo Ying Fan Peng Yuan Pin Zhang Qing Li Fei Ma Binghe Xu |
| author_sort | Yiqun Li |
| collection | DOAJ |
| description | BackgroundTo characterize the clinical and pathological features and survival of patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer in China.MethodsThe China National Cancer Center database was used to identify 1,433 metastatic breast cancer patients with HER2-negative disease diagnosed between 2005 and 2015. Clinicopathological features, survival, and prognosis information were extracted. Overall survival (OS) was estimated using the Kaplan–Meier method and compared using the log-rank test. Prognostic factors associated with OS were analyzed using Cox regression model with 95% confidence interval (95% CI).ResultsThere were 618 (43.1%) and 815 (56.9%) HER2-low and HER2-zero tumors out of 1,433 tumors, respectively. The proportion of hormone receptor (HR)-positive tumors was significantly higher in HER2-low tumors than in those with HER2-zero tumors (77.8% vs. 69.2%, p < 0.001). Patients with HER2-low tumors survived significantly longer than those with HER2-zero tumors in the overall population (48.5 months vs. 43.0 months, p = 0.004) and HR-positive subgroup (54.9 months vs. 48.1 months, p = 0.011), but not in the HR-negative subgroup (29.5 months vs. 29.9 months, p = 0.718). Multivariate regression analysis revealed that HER2-low tumors were independently associated with increased OS in HER2-negative population (HR: 0.85, 95% CI: 0.73–0.98, p = 0.026).ConclusionOur findings demonstrate that HER2-low tumors could be identified as a more distinct clinical entity from HER2-zero tumors, especially for the HR-positive subgroup. A more complex molecular landscape of HER2-low breast cancer might exist, and more precise diagnostic algorithms for HER2 testing could be investigated, thus offering new therapeutic targets for breast cancer treatment. |
| first_indexed | 2024-12-24T01:45:00Z |
| format | Article |
| id | doaj.art-19ed20b5eea34fae87db2f216a0e0e79 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-24T01:45:00Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-19ed20b5eea34fae87db2f216a0e0e792022-12-21T17:21:54ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-01-011110.3389/fonc.2021.774577774577In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, ChinaYiqun LiNilupai AbudureheiyimuHongnan MoXiuwen GuanShaoyan LinZijing WangYimeng ChenShanshan ChenQiao LiRuigang CaiJiayu WangYang LuoYing FanPeng YuanPin ZhangQing LiFei MaBinghe XuBackgroundTo characterize the clinical and pathological features and survival of patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer in China.MethodsThe China National Cancer Center database was used to identify 1,433 metastatic breast cancer patients with HER2-negative disease diagnosed between 2005 and 2015. Clinicopathological features, survival, and prognosis information were extracted. Overall survival (OS) was estimated using the Kaplan–Meier method and compared using the log-rank test. Prognostic factors associated with OS were analyzed using Cox regression model with 95% confidence interval (95% CI).ResultsThere were 618 (43.1%) and 815 (56.9%) HER2-low and HER2-zero tumors out of 1,433 tumors, respectively. The proportion of hormone receptor (HR)-positive tumors was significantly higher in HER2-low tumors than in those with HER2-zero tumors (77.8% vs. 69.2%, p < 0.001). Patients with HER2-low tumors survived significantly longer than those with HER2-zero tumors in the overall population (48.5 months vs. 43.0 months, p = 0.004) and HR-positive subgroup (54.9 months vs. 48.1 months, p = 0.011), but not in the HR-negative subgroup (29.5 months vs. 29.9 months, p = 0.718). Multivariate regression analysis revealed that HER2-low tumors were independently associated with increased OS in HER2-negative population (HR: 0.85, 95% CI: 0.73–0.98, p = 0.026).ConclusionOur findings demonstrate that HER2-low tumors could be identified as a more distinct clinical entity from HER2-zero tumors, especially for the HR-positive subgroup. A more complex molecular landscape of HER2-low breast cancer might exist, and more precise diagnostic algorithms for HER2 testing could be investigated, thus offering new therapeutic targets for breast cancer treatment.https://www.frontiersin.org/articles/10.3389/fonc.2021.774577/fullHER2-lowclinicopathological featuresmetastatic breast cancersurvivalprognosis |
| spellingShingle | Yiqun Li Nilupai Abudureheiyimu Hongnan Mo Xiuwen Guan Shaoyan Lin Zijing Wang Yimeng Chen Shanshan Chen Qiao Li Ruigang Cai Jiayu Wang Yang Luo Ying Fan Peng Yuan Pin Zhang Qing Li Fei Ma Binghe Xu In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China Frontiers in Oncology HER2-low clinicopathological features metastatic breast cancer survival prognosis |
| title | In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China |
| title_full | In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China |
| title_fullStr | In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China |
| title_full_unstemmed | In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China |
| title_short | In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China |
| title_sort | in real life low level her2 expression may be associated with better outcome in her2 negative breast cancer a study of the national cancer center china |
| topic | HER2-low clinicopathological features metastatic breast cancer survival prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.774577/full |
| work_keys_str_mv | AT yiqunli inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT nilupaiabudureheiyimu inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT hongnanmo inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT xiuwenguan inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT shaoyanlin inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT zijingwang inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT yimengchen inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT shanshanchen inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT qiaoli inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT ruigangcai inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT jiayuwang inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT yangluo inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT yingfan inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT pengyuan inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT pinzhang inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT qingli inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT feima inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina AT binghexu inreallifelowlevelher2expressionmaybeassociatedwithbetteroutcomeinher2negativebreastcancerastudyofthenationalcancercenterchina |